Surmodics, Inc. recently announced early results from its PROWL registry study of a subset of 60 real-world patients with acute ...

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced ...

A new research paper titled "Initiation of tumor dormancy by the lymphovascular embolus" has been published in Oncotarget ...

Both our experimental as well as observational studies indicate that in vivo lymphovascular tumor emboli and their in vitro spheroid equivalent ...

A study led by clinician-scientists and researchers from the National Cancer Centre Singapore (NCCS) and Singapore General Hospital (SGH) has determined the benefits of using a higher dosage of ...